

Specimen ID:
Control ID:

Acct #:

Phone:

Rte:



Patient Details		Specimen Details		Physician Details	
DOB:		Date collected:		Ordering:	
Age(y/m/d):		Date received:		Referring:	
Gender:	SSN:	Date entered:		ID:	
Patient ID:		Date reported:		NPI:	

General Comments & Additional Information

Clinical Info: NORMAL REPORT

Ordered Items

NMR LipoProf+Graph

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
NMR LipoProf+Graph					
LDL Particle Number					01
LDL-P ^A	643		nmol/L	<1000	01
		Low		< 1000	
		Moderate		1000 - 1299	
		Borderline-High		1300 - 1599	
		High		1600 - 2000	
		Very High		> 2000	
Lipids					01
LDL-C ^A	77		mg/dL	0 - 99	01
		Optimal		< 100	
		Above optimal		100 - 129	
		Borderline		130 - 159	
		High		160 - 189	
		Very high		> 189	
Comment:					01
LDL-C is inaccurate if patient is non-fasting.					
HDL-C ^A	83		mg/dL	>39	01
Triglycerides ^A	57		mg/dL	0 - 149	01
Cholesterol, Total ^A	171		mg/dL	100 - 199	01
LDL and HDL Particles					01
HDL-P (Total) ^A	37.7		umol/L	>=30.5	01
Small LDL-P ^A	<90		nmol/L	<=527	01
LDL Size ^A	21.2		nm	>20.5	01

**** INTERPRETATIVE INFORMATION****

PARTICLE CONCENTRATION AND SIZE

	<--Lower CVD Risk		Higher CVD Risk-->		
	Percentile	in	Reference Population		
LDL AND HDL PARTICLES					
HDL-P (total)	High	75th	50th	25th	Low
	>34.9	34.9	30.5	26.7	<26.7
Small LDL-P	Low	25th	50th	75th	High
	<117	117	527	839	>839
LDL Size	<-Large (Pattern A)->		<-Small (Pattern B)->		
	23.0	20.6	20.5	19.0	

FINAL REPORT

Patient:
 DOB:

Patient ID:

Control ID:

 Specimen ID:
 Date collected:

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB

Comment:	Small LDL-P and LDL Size are associated with CVD risk, but not after LDL-P is taken into account.				01
Insulin Resistance Score					01
LP-IR Score ^A	<25			<=45	01
INSULIN RESISTANCE MARKER					
<--Insulin Sensitive Insulin Resistant-->					
Percentile in Reference Population					
Insulin Resistance Score					
LP-IR Score	Low	25th	50th	75th	High
	<27	27	45	63	>63
Comment:	LP-IR Score is inaccurate if patient is non-fasting. The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment.				01
NMR PDF Image					01

Comments:

^A This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

Specimen Number		Patient ID		Account Number	Account Phone	Account Fax
Patient Last Name		Patient First Name		Account Address		
Age	Date of Birth	Sex	Fasting			
Control Number		NPI				
Date Collected	Date Entered	Date and Time Reported		Physician ID & Name		Page Number

❖ **NMR LipoProfile® test**

Reference Interval¹

	Percentile ¹	20th	50th	80th	95th
	Low	Moderate	Borderline High	High	Very High
LDL-P (LDL Particle Number)	643	< 1000	1000 - 1299	1300 - 1599	1600 - 2000
				1600 - 2000	> 2000

1. Reference population (5,362 men and women) not on lipid medication enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA). Mora, et al. Atherosclerosis 2007.


❖ **Lipids**

	mg/dL	Optimal	Near or Above Optimal	Borderline High	High	Very High
LDL-C (calculated)	77	< 100	100 - 129	130 - 159	160 - 189	≥ 190

HDL-C	83	Triglycerides	57	Total Cholesterol	171
	Desirable ≥ 40		Desirable < 150		Desirable < 200

LDL-C is inaccurate if patient is non-fasting.

Historical Reporting



❖ This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the US Food and Drug Administration.



Issued or Pending
PATENTS

The NMR LipoProfile® test may be covered by one or more issued or pending patents, including U.S. Patent Nos. 6,518,069; 6,576,471; 6,653,140; and 7,243,030

CLIA Number

Specimen Number		Patient ID		Account Number	Account Phone	Account Fax
Patient Last Name		Patient First Name		Account Address		
Age	Date of Birth	Sex	Fasting			
Control Number		NPI		Physician ID & Name		
Date Collected	Date Entered	Date and Time Reported				

PARTICLE CONCENTRATION AND SIZE



Clinician Notes

❖ This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the US Food and Drug Administration.

① LipoScience reference population comprises 4,588 men and women without known CVD or diabetes and not on lipid medication.

② Shalurova I et al., Metab Syndr Relat Disord 2014; 12:422-9.

③ Mackey RH et al., Diab Care 2015; 38:628-36.